Pancreatic Cancer News and Research RSS Feed - Pancreatic Cancer News and Research

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
KIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate

KIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate

There is an urgent need for medical agents to treat metastatic tumors. In case of pancreatic cancer, one of the most aggressive types of cancer that is often detected late, 95% of the patients die within five years after the diagnosis. [More]
State highlights: Calif. hospital accused of patient dumping; Wash. mental health changes

State highlights: Calif. hospital accused of patient dumping; Wash. mental health changes

Los Angeles City Atty. Mike Feuer has filed a lawsuit accusing Glendale Adventist Medical Center of dumping mentally ill and disabled homeless patients on L.A.'s skid row over the last four years. The six-page complaint, filed Wednesday in Los Angeles County Superior Court, said the hospital improperly transported elderly and dependent patients to the downtown Los Angeles neighborhood, a 50-block area "known for extreme poverty, homelessness, rampant sale and use of illegal drugs and violent crime" (Holland, 8/22). [More]
Study links gum disease to lung disease, cancer and heart failure

Study links gum disease to lung disease, cancer and heart failure

Most people are very familiar with the reality that, if they don't practice regular brushing and overall good dental hygiene, they are at risk for developing gum disease. Less well known is the full extent of the potential harm caused by gum disease. [More]
Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

A leukemia drug called dasatinib shows promise for treating skin, breast and several other cancers, according to researchers at Loyola University Chicago Stritch School of Medicine. [More]
Injections of anaerobic bacteria can shrink tumors in rats, dogs and human

Injections of anaerobic bacteria can shrink tumors in rats, dogs and human

Deep within most tumors lie areas that remain untouched by chemotherapy and radiation. These troublesome spots lack the blood and oxygen needed for traditional therapies to work, but provide the perfect target for a new cancer treatment using bacteria that thrive in oxygen-poor conditions. [More]
Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share. [More]
Cancer Research UK, CRT and Astellas collaborate to find new drug targets for pancreatic cancer

Cancer Research UK, CRT and Astellas collaborate to find new drug targets for pancreatic cancer

Cancer Research UK and its commercial arm, Cancer Research Technology (“CRT”), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, “Astellas”) to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer. [More]
Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014. [More]

Long-term survival from pancreatic cancer fails to improve in 40 years

Long-term survival from pancreatic cancer has failed to improve in 40 years - with the outlook remaining the lowest of the 21 most common cancers, according to new figures published by Cancer Research UK today. [More]
New genetic markers signal increased risk of developing pancreatic cancer

New genetic markers signal increased risk of developing pancreatic cancer

A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, report scientists from Dana-Farber Cancer Institute. [More]
New use for old drug provides hope for patients with pancreatic cancer

New use for old drug provides hope for patients with pancreatic cancer

Cancer Research UK scientists have found a new use for an old drug by showing that it shrinks a particular type of pancreatic cancer tumour and stops it spreading, according to research published in Gut. [More]
CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil. [More]
Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer. [More]
Saltier intravenous drip reduces overall rate of complications by 25% after Whipple surgery

Saltier intravenous drip reduces overall rate of complications by 25% after Whipple surgery

Adequate hydration via a saline drip is essential during surgery, but recent reports suggest that getting the balance of salt and water just right could have an important impact on patient recovery. [More]
Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Oncolytics Biotech Inc. today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). [More]
Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). [More]

Researchers receive over $1M to study molecular foundations of pancreatic cancer

Alexandros Tzatsos, M.D., Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, was awarded over one million dollars in grants from the National Institutes of Health to study the molecular foundations of pancreatic cancer. [More]
Extract of Chinese herb thunder god vine suppresses pancreatic cancer cell

Extract of Chinese herb thunder god vine suppresses pancreatic cancer cell

A diagnosis of pancreatic cancer—the fourth most common cause of cancer death in the U.S.—can be devastating. Due in part to aggressive cell replication and tumor growth, pancreatic cancer progresses quickly and has a low five-year survival rate (less than 5 percent). [More]
Researchers identify new protein as possible therapeutic target for pancreatic cancer

Researchers identify new protein as possible therapeutic target for pancreatic cancer

Researchers from IMIM (Hospital del Mar Medical Research Institute) have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer. [More]
Some cancer patients with aggressive tumors may benefit from anti-inflammatory drugs

Some cancer patients with aggressive tumors may benefit from anti-inflammatory drugs

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis. [More]